Chinese regulator surprises pharma with clinical data self-audit notice
This article was originally published in SRA
Executive Summary
A China Food and Drug Administration announcement released on July 22 is requiring the drug applicants in over 1,600 pending product approvals to conduct self-audits of the clinical data and submit an electronic version of the reports to the CFDA’s Center for Drug and Food Inspection1.
You may also be interested in...
China Clarifies Position on Forged Trial Data As 30 Applications Are Rejected
As more new drug applications get rejected under the China Food and Drug Administration’s drive to stamp out trial data forgery, the regulator has issued draft guidance to clarify its position on data integrity breaches.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.